Sugi Predict

Sugi Predict / Compounds / SCHEMBL5656464

SCHEMBL5656464

SCHEMBL5656464

CC(C)(C)[Si](C)(C)Oc1ccc(C2(c3ccc(O[Si](C)(C)C(C)(C)C)cc3)C(=O)Nc3ccccc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.59
▸ LMNA P02545 2/20 0.55
▸ CHRM2 P08172 1/20 0.54
▸ ADORA3 P0DMS8 1/20 0.54
▸ KCNH2 Q12809 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PDK2 Q15119 1/20 0.40
▸ PDK4 Q16654 1/20 0.40
▸ MGAM O43451 4/20 0.39
▸ GAA P10253 4/20 0.39
▸ SI P14410 4/20 0.39
▸ MGAM2 Q2M2H8 4/20 0.39
▸ PREP P48147 2/20 0.39
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA9 Q16790 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658522 0.81 MAPT (0.53) MAPTLMNACHRM2ADORA3KCNH2
SCHEMBL17813120 0.79 MAPT (0.69) MAPTLMNACHRM2ADORA3KCNH2
Oxyphenisatin Acetate SCHEMBL7528210 0.74 MAPT (1.00) MAPTLMNACHRM2ADORA3KCNH2
Oxyphenisatin Acetate SCHEMBL555117 0.74 MAPT (1.00) MAPTLMNACHRM2ADORA3KCNH2
Oxyphenisatin Acetate SCHEMBL29737232 0.74 MAPT (1.00) MAPTLMNACHRM2ADORA3KCNH2
SCHEMBL3198592 0.73 CHRM2 (0.78) MAPTLMNACHRM2ADORA3KCNH2
SCHEMBL2715686 0.73 LMNA (1.00) MAPTLMNACHRM2ADORA3KCNH2
SCHEMBL25502467 0.72 CHRM2 (0.82) MAPTLMNACHRM2ADORA3KCNH2
SCHEMBL20358438 0.72 CFTR (0.56) MAPTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL23392503 0.72 PREP (0.40) PREPCA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 — — US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 — — US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 — — US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 — — EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MAPT 3588/4885LMNA 3323/4885CHRM2 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.